We assessed FAS and FAS-L gene polymorphisms and messenger RNA (mRNA) levels in patients with recurrent pregnancy loss (RPL). This case–control study compared 129 women with RPL with 235 healthy multiparous women (control group). Genomic DNA and total mRNA were extracted from whole blood, and polymorphisms genotyping was performed by polymerase chain reaction (PCR). Messenger RNA expression levels were analyzed by real-time PCR. Data were analyzed by chi-square and Fisher exact tests; P < .05 was considered significant. There were no significant differences in the FAS (670 A/G) genotype or allelic frequencies between the RPL and control groups. We found significant differences in the FAS-L (844 C/T) genotype and allelic frequencies between women with RPL and controls. Patients with RPL had significantly higher FAS-L expression. Our data suggest that FAS-L gene polymorphism is associated with increased susceptibility to RPL. Moreover, women with RPL seem to abnormally express FAS-FAS-L molecules.
KiwiR. Recurrent pregnancy loss: evaluation and discussion of the causes and their management. Cleve Clin J Med. 2006;73(10):913–921.
3.
AschkenaziSStraszewskiSVerwerKMDifferential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod. 2002;66(6):1853–1861.
4.
AbrahamsVMStraszewski-ChavezSLGullerSMorG. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod. 2004;10(1):55–63.
5.
CrockerIPCooperSOngSCBakerPN. Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol. 2003;162(2):637–643.
6.
HoshimotoKHayashiMOhkuraT. Plasma levels of soluble Fas during normal pregnancy. Gynecol Obstet Invest. 2001;51(2):96–98.
7.
ZongWXThompsonCB. Necrotic death as a cell fate. Genes Dev. 2006;20(1):1–15.
8.
ChoiHKChoiBCLeeSHKimJWChaKYBaekKH. Expression of angiogenesis- and apoptosis-related genes in chorionic villi derived from recurrent pregnancy loss patients. Mol Reprod Dev. 2003;66(1):24–31.
9.
LevyRNelsonDM. To be, or not to be, that is the question. Apoptosis in human trophoblast. Placenta. 2000;21(1):1–13.
10.
PatelTGoresGJ. Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. Liver Transpl Surg. 1998;4(1):42–50.
11.
NealeDMMorG. The role of Fas mediated apoptosis in preeclampsia. J Perinat Med. 2005;33(6):471–477.
12.
MinasVJeschkeUKalantaridouSNAbortion is associated with increased expression of FasL in decidual leukocytes and apoptosis of extravillous trophoblasts: a role for CRH and urocortin. Mol Hum Reprod. 2007;13(9):663–673.
13.
SunTZhouYLiHFASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202(7):967–974.
14.
WuJMetzCXuXA novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–138.
15.
LiakouliVManettiMPaciniAThe -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis. 2009;68(4):584–590.
16.
KangSDongSMSeoSSKimJWParkSY. FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180(1):1–5.
17.
LiCLarsonDZhangZPolymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006;16(4):253–263.
18.
GustincichSManfiolettiGDel SalGSchneiderCCarninciP.A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques. 1991;11(3):298–300, 302.
19.
FuksAPartonLAPolavarapuSPolymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies. Am J Obstet Gynecol. 2005;193(3 pt 2):1132–1136.
20.
DupontWDPlummerWDJrPower and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2):116–128.
21.
PfafflMWHorganGWDempfleL. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.
22.
AllaireADBallengerKAWellsSRMcMahonMJLesseyBA. Placental apoptosis in preeclampsia. Obstet Gynecol2000;96(2):271–276.
23.
HammerABlaschitzADaxbockCWalcherWDohrG. Fas and Fas-ligand are expressed in the uteroplacental unit of first-trimester pregnancy. Am J Reprod Immunol. 1999;41(1):41–51.
24.
EideIPIsaksenCVSalvesenKAFetal growth restriction is associated with reduced FasL expression by decidual cells. J Reprod Immunol2007;74(1-2):7–14.
25.
TurnerAKBegonMJacksonJABradleyJEPatersonS.Genetic diversity in cytokines associated with immune variation and resistance to multiple pathogens in a natural rodent population. PLoS Genet. 2011;7(10):e1002343.
26.
NovakovicBSafferyR. The ever growing complexity of placental epigenetics - Role in adverse pregnancy outcomes and fetal programming. Placenta. 2012;33(12):959–970.
27.
HebertDNMolinariM.In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev. 2007;87(4):1377–1408.
28.
CiarmelaPBoschiSBloiseEPolymorphisms of FAS and FAS ligand genes in preeclamptic women. Eur J Obstet Gynecol Reprod Biol. 2010;148(2):144–146.
29.
NairRRKhannaASinghK. Association of FAS -1377 G>A and FAS -670 A>G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol. 2012;93(2):114–118.
30.
HuangQRMorrisDManoliosN. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34(8-9):577–582.
